Shares of Evolus Inc (NASDAQ:EOLS) have been assigned an average rating of “Buy” from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $26.33.
Several brokerages have recently commented on EOLS. HC Wainwright restated a “buy” rating on shares of Evolus in a research note on Tuesday, November 5th. Leerink Swann initiated coverage on shares of Evolus in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective for the company. Svb Leerink initiated coverage on shares of Evolus in a report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 target price on the stock. Mizuho reiterated a “buy” rating and set a $30.00 target price on shares of Evolus in a report on Thursday, September 5th. Finally, Zacks Investment Research upgraded shares of Evolus from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of Evolus by 12.2% during the 2nd quarter. BlackRock Inc. now owns 994,396 shares of the company’s stock worth $14,540,000 after purchasing an additional 107,946 shares during the last quarter. Vanguard Group Inc. raised its holdings in Evolus by 46.3% in the second quarter. Vanguard Group Inc. now owns 710,230 shares of the company’s stock worth $10,384,000 after purchasing an additional 224,758 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Evolus during the second quarter valued at about $4,167,000. State Street Corp lifted its position in shares of Evolus by 21.6% during the third quarter. State Street Corp now owns 230,987 shares of the company’s stock valued at $3,608,000 after buying an additional 41,046 shares during the last quarter. Finally, Wafra Inc. lifted its position in shares of Evolus by 106.2% during the second quarter. Wafra Inc. now owns 203,263 shares of the company’s stock valued at $2,972,000 after buying an additional 104,706 shares during the last quarter. Institutional investors and hedge funds own 16.94% of the company’s stock.
Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, November 4th. The company reported ($0.78) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.55. The firm had revenue of $13.17 million for the quarter, compared to the consensus estimate of $5.18 million. On average, sell-side analysts anticipate that Evolus will post -3.75 earnings per share for the current fiscal year.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.